Full Answer
When is Biotron's next earnings date?
Biotron is scheduled to release its next quarterly earnings announcement on Thursday, August 25th 2022. View our earnings forecast for Biotron .
Who are Biotron's key executives?
Biotron's management team includes the following people: Dr. Michelle Miller BSc. , GCertAppFin, MSc., Ph.D., MD & Exec. Director Mr. Peter James...
Who are some of Biotron's key competitors?
Some companies that are related to Biotron include 3SBio (TRSBF) , 45525 (CUR.TO) (CUR) , Abattis Bioceuticals (ATTBF) , Abcam (ABCZF) , Abzen...
What other stocks do shareholders of Biotron own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Biotron investors own include TPG Co. Limited (TPM.AX) (TP...
What is Biotron's stock symbol?
Biotron trades on the ASX under the ticker symbol "BIT."
How much money does Biotron make?
Biotron (ASX:BIT) has a market capitalization of $0.00 and generates $1.41 million in revenue each year.
How many employees does Biotron have?
Biotron employs 3 workers across the globe.
What is Biotron's official website?
The official website for Biotron is www.biotron.com.au .
How can I contact Biotron?
Biotron's mailing address is 100 Bellevue Pkwy, Wilmington, Delaware 19809-3700 . The company can be reached via phone at 61 2 9805 0488 .
Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Biotron Drug Effective Against COVID-19 In Animals
The Directors of Biotron Limited (ASX: BIT) are pleased to announce that the Company's lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research Institute, La Jolla, CA, USA.
We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
About Biotron
Biotron Limited, a biotechnology company, engages in the developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections.
Who are some of Biotron's key competitors?
Some companies that are related to Biotron include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abcam (ABCZF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), ALK-Abello A/S (AKBLF), Almirall (LBTSF), Amarantus BioScience (AMBS) and Amplia Therapeutics (ATX). View all of BIT's competitors..
What other stocks do shareholders of Biotron own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Biotron investors own include TPG Co.
How much money does Biotron make?
Biotron has a market capitalization of $0.00 and generates $1.46 million in revenue each year.
Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Biotron Drug Effective Against COVID-19 In Animals
The Directors of Biotron Limited (ASX: BIT) are pleased to announce that the Company's lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research Institute, La Jolla, CA, USA.
We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Snapshot
BIT's Principal Activity is the funding and management of intermediate and applied biotechnology research and development projects.
Corporate Overview
Biotron Limited (BIT) is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and a promising preclinical program for HBV.
Director Transactions
BIT directors must report any change in shareholding to the ASX within 5 business days.
Historical Data
You must be logged in to access this feature. Please sign up for free or login .
BIT Stock Overview
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
Valuation
Is Biotron undervalued compared to its fair value and its price relative to the market?
Future Growth
How is Biotron forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Dividend
What is Biotron current dividend yield, its reliability and sustainability?
Management
How experienced are the management team and are they aligned to shareholders interests?
Ownership
Who are the major shareholders and have insiders been buying or selling?
Why Biotron, Fortescue, Ramelius, & Temple & Webster are storming higher
In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to snap its losing streak with a solid gain. At …
Why Biotron, Karoon Energy, Pro Medicus, & WiseTech Global are pushing higher
The S&P/ASX 200 index (ASX: XJO) has followed the lead of U.S. markets and is tumbling lower on Thursday. In …
These ASX shares are fighting the spread of coronavirus
The spread of coronavirus has infected global share markets with the contagion of fear. The S&P/ASX 200 Index (INDEXASX: XJO) …